Ethan Kass, DO
Psychiatry · Coral Springs, FLNPI 1912991811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 37.4% of the total. Reporting peaked in 2022 at $362 and has fallen 71.2% since, to $104 in 2023.
Across 26 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$301
- Bausch Health US, LLC$200
- Sunovion Pharmaceuticals Inc.$109
- Johnson & Johnson$101
- Alkermes, Inc.$95
Across 94 payments — averaging $17,014 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$627K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$510K
- Janssen Research & Development, LLC$302K
- Takeda Pharmaceuticals U.S.A., Inc.$123K
- Boehringer Ingelheim$38K
- Boehringer Ingelheim Pharma GmbH & Co.kg$68
What the payments were for
- Food & beverage$806100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $301 |
| Bausch Health US, LLC | 12 | $200 |
| Sunovion Pharmaceuticals Inc. | 8 | $109 |
| Johnson & Johnson | 1 | $101 |
| Alkermes, Inc. | 2 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$806 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $107,729 |
| Abilify MaintenaAripiprazole | 13 | $35,969 |
| Aripiprazole | 50 | $5,952 |
| Duloxetine Hcl | 226 | $4,500 |
| Bupropion XlBupropion Hcl | 244 | $3,877 |
| Alprazolam | 554 | $3,690 |
| Clonazepam | 300 | $3,118 |
| Quetiapine Fumarate | 134 | $2,957 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 65 | $2,822 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 31 | $2,755 |
| Ziprasidone Hcl | 22 | $2,553 |
| Trazodone Hcl | 280 | $2,504 |
| Olanzapine | 110 | $2,499 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 109 | $2,408 |
| Gabapentin | 78 | $1,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $301 | $107,72915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Coral Springs
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.